-Other (income) expense adjustment
(10)Income tax adjustment
(11)*Noncontrolling Interest adjustments:Other revenues
-(31)Research and development
1,4176,094Selling, general and administrative1,0633,222Other income (expense)
-(3,848)Less amount attributable to noncontrolling interest
(3,203)(5,750)(28,267)109,610ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.
$ 300,996$ 309,239BASIC ADJUSTED INCOME PER COMMON SHARE
4.12DILUTED ADJUSTED INCOME PER COMMON SHARE
3.81WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING
76,21375,092WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION
82,87181,223* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($56.0M in 2011; $58.0M in 2010), the reversal of a royalty accrual related to AMRIX sales milestones that are no longer expected to be payable ($27.8M in 2011), accelerated depreciation related to restructuring ($10.7M in 2010), amortization of inventory revaluation related to Mepha ($5.0M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010).(2) To exclude accelerated depreciation related to restructuring.(3) In 2011, to exclude charges related to the unsolicited proposal we received from Valeant Pharmaceuticals International and the Agreement and Plan of Merger with Teva Pharmaceutical Industries Ltd. ($20.9M), and charges associated with recent acquisitions. In 2010, to exclude charges related to t
|SOURCE Cephalon, Inc.|
Copyright©2010 PR Newswire.
All rights reserved